keyword
MENU ▼
Read by QxMD icon Read
search

Cancer death dying chemotherapy

keyword
https://www.readbyqxmd.com/read/29883922/multiple-primary-tumors-colorectal-carcinoma-and-non-hodgkin-s-lymphoma
#1
Diana A Pantoja Pachajoa, Marco Antonio Bruno, Fernando A Alvarez, Germán Viscido, Facundo Mandojana, Alejandro Doniquian
INTRODUCTION: Colorectal cancer (CRC) is the third most commonly diagnosed cancer, whereas lymphoma is the sixth leading cause of cancer death, 90% of which corresponds to non-Hodgkin's lymphoma (NHL). The association of these two primary tumors, a solid tumor with an hematological malignancy, is very uncommon. PRESENTATION OF CASE: We report the case of a 47-year-old man who presented with abdominal pain, a right upper quadrant mass and 12 kg of weight loss in 9 months...
May 30, 2018: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29880231/pembrolizumab-versus-paclitaxel-for-previously-treated-advanced-gastric-or-gastro-oesophageal-junction-cancer-keynote-061-a-randomised-open-label-controlled-phase-3-trial
#2
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun C Chung, Kei Muro, Eray Goekkurt, Wasat Mansoor, Raymond S McDermott, Einat Shacham-Shmueli, Xinqun Chen, Carlos Mayo, S Peter Kang, Atsushi Ohtsu, Charles S Fuchs
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine. METHODS: This randomised, open-label, phase 3 study was done at 148 medical centres in 30 countries. Eligible patients were randomised (1:1) in blocks of four per stratum with an interactive voice-response and integrated web-response system to receive either pembrolizumab 200 mg every 3 weeks for up to 2 years or standard-dose paclitaxel...
June 4, 2018: Lancet
https://www.readbyqxmd.com/read/29879136/medical-care-costs-of-cancer-in-the-last-year-of-life-using-national-health-insurance-data-in-korea
#3
Mihai Park, Inmyung Song
BACKGROUND: Medical care of cancer patients at the end-of-life is costly. This study aims to describe the monthly trends of EOL medical care, drug therapy, and chemotherapy costs per patient with cancer in the last year of life in the inpatients vs. outpatient setting for the 13 most prevalent cancers in Korea. METHODS: Using the Health Insurance Review and Assessment Service (HIRA) database, we identified the patients who had been treated for the primary diagnoses of one of the 13 most prevalent cancers in Korea and died between January 1, 2013 and December 31, 2015...
2018: PloS One
https://www.readbyqxmd.com/read/29867351/cannabinoids-in-glioblastoma-therapy-new-applications-for-old-drugs
#4
REVIEW
Claudia A Dumitru, I Erol Sandalcioglu, Meliha Karsak
Glioblastoma (GBM) is the most malignant brain tumor and one of the deadliest types of solid cancer overall. Despite aggressive therapeutic approaches consisting of maximum safe surgical resection and radio-chemotherapy, more than 95% of GBM patients die within 5 years after diagnosis. Thus, there is still an urgent need to develop novel therapeutic strategies against this disease. Accumulating evidence indicates that cannabinoids have potent anti-tumor functions and might be used successfully in the treatment of GBM...
2018: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/29861876/pore-forming-channels-as-a-drug-delivery-system-for-photodynamic-therapy-in-cancer-associated-with-nanoscintillators
#5
REVIEW
Luiz Anastacio Alves, Leonardo Braga Ferreira, Paulo Furtado Pacheco, Edith Alejandra Carreño Mendivelso, Pedro Celso Nogueira Teixeira, Robson Xavier Faria
According to the World Health Organization (WHO), cancer is one of main causes of death worldwide, with 8.2 million people dying from this disease in 2012. Because of this, new forms of treatments or improvement of current treatments are crucial. In this regard, Photodynamic therapy (PDT) has been used to successfully treat cancers that can be easily accessed externally or by fibre-optic endoscopes, such as skin, bladder and esophagus cancers. In addition, this therapy can used alongside radiotherapy and chemotherapy in order to kill cancer cells...
May 18, 2018: Oncotarget
https://www.readbyqxmd.com/read/29804327/risk-factors-for-competing-noncancer-mortality-after-definitive-treatment-for-advanced-stage-head-and-neck-cancer
#6
Yong Han Kim, Jong-Lyel Roh, Sung-Bae Kim, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim
OBJECTIVE: Patients with head and neck cancer (HNC) can die of index tumor progression and second tumor or noncancer causes. Here, we investigated the risk factors for competing noncancer mortality (NCM) in a prospective cohort of patients with advanced-stage HNC. MATERIALS AND METHODS: A prospective observational study was conducted with 604 patients who underwent definitive treatment for advanced-stage HNC between 2010 and 2015. Main outcomes were NCM and cancer mortality (CM) defined as death from noncancer causes and HNC or second cancers, respectively...
May 27, 2018: Oral Diseases
https://www.readbyqxmd.com/read/29779035/combined-coronary-artery-bypass-graft-cabg-surgery-and-lung-resection-for-lung-cancer-in-patients-more-than-50-years-of-age
#7
Ban Liu, Chao Chen, Chang Gu, Qianfan Li, Jingjing Liu, Yiwei Pu, Yu Lin, Zilun Wei, Zhi Li, Yangyang Zhang
BACKGROUND The co-existence of coronary heart disease (CHD) and lung cancer is increasing in an increasingly aging population. The aim of this study was to evaluate patient outcome from combined off-pump coronary artery bypass graft (CABG) surgery and lung resection in patients more than 50 years-of-age. MATERIAL AND METHODS A retrospective clinical study of 23 patients with a mean age of 70.2±8.4 years (range, 51-86 years) included 18 men and five women with CHD and lung cancer who underwent a single operation with combined off-pump CABG surgery and lung resection, for non-small cell lung cancer (NSCLC) (n=22) and small cell lung cancer (n=1)...
May 20, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29757869/end-of-life-care-for-patients-with-advanced-ovarian-cancer-is-aggressive-despite-hospice-intervention-a-population-based-study
#8
Jui-Kun Chiang, Chun-Shuo Hsu, Chih-Wen Lin, Yee-Hsin Kao
OBJECTIVE: To date, few studies have examined end-of-life (EOL) care and healthcare costs for patients with ovarian cancer. We evaluated the effects of hospice care on the quality of EOL care and healthcare costs for patients with ovarian cancer in the final month of life. MATERIALS AND METHODS: We conducted a population-based study and analyzed data from Taiwan's Longitudinal Health Insurance Database, which contains claims information for medical records of patients, healthcare costs, and insurance system exit dates: our proxy for death between 1997 and 2011...
May 11, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29756612/cancer-of-the-head-and-neck-a-set-of-indicators-based-on-register-and-administrative-data
#9
A Andreano, M Ansarin, D Alterio, R Bruschini, M G Valsecchi, A G Russo
Head and neck (H&N) tumours are a heterogeneous group of neoplasms with 5-year relative survival ranging from about 25% for the hypopharynx to 60% for the larynx in Europe. To improve survival rates, along with therapeutic improvements, it is important to standardise and optimise care received by patients with H&N tumours across different healthcare providers. To reach this goal, it is necessary to evaluate adherence to standards of received care at a population level. Published guidelines can serve as the basis to develop indicators, which can be computed from administrative health databases, measuring the adherence to specific recommendations at the individual level in unselected H&N cancer patients, identified from a population cancer register...
February 2018: Acta Otorhinolaryngologica Italica
https://www.readbyqxmd.com/read/29742292/timing-of-palliative-care-needs-reporting-and-aggressiveness-of-care-near-the-end-of-life-in-metastatic-lung-cancer-a-national-registry-based-study
#10
François Goldwasser, Pascale Vinant, Régis Aubry, Philippe Rochigneux, Yvan Beaussant, Olivier Huillard, Lucas Morin
BACKGROUND: Early integration of palliative care for patients with metastatic lung cancer improves their quality of life and survival and reduces the aggressiveness of care near the end of life. This study examined the association between the timing of palliative care needs reporting and the aggressiveness of end-of-life care. METHODS: This retrospective cohort study used the French National Hospital Registry to identify all hospitalized adults (≥20 years old) who died of metastatic lung cancer in France between 2010 and 2013...
May 9, 2018: Cancer
https://www.readbyqxmd.com/read/29739108/using-blood-and-plasma-micrornas-as-a-non-invasive-biomarker-in-patients-with-colorectal-cancer
#11
Horatiu Stefanescu, Delia Muntean, Ciprian Pilut, Mircea Diaconu, Roxana Popescu, Delia Hutanu, Marius Moise, Lighezan Diana, Razvan Nitu, Alina Popa Cherecheanu, Silvius Negoita, Ciprian V Iovan, Emil Ungureanu, Valentin Calu, Ioana Ciuca
BACKGROUND: A high percentage of oncological patients die yearly because of colorectal cancer (CRC). Worldwide, CRC represents the fourth leading cause of death among oncological patients. Numerous studies have been conducted in order to identify new biomarkers for the early diagnosis of patients with CRC. From this point of view, an ideal biomarker is represented by the expression of microRNAs. In this paper, we wish to summarize the expressions of microRNAs in CRC and to present the pathophysiological and genetic interactions that microRNAs have with protein systems in these patients...
March 1, 2018: Clinical Laboratory
https://www.readbyqxmd.com/read/29727916/characteristics-and-outcomes-of-patients-with-hematologic-malignancies-receiving-chemotherapy-in-the-intensive-care-unit
#12
Stephen M Pastores, Debra A Goldman, David J Shaz, Natalie Kostelecky, Ryan J Daley, Tim J Peterson, Kay See Tan, Neil A Halpern
BACKGROUND: The objective of this study was to evaluate the short-term and long-term outcomes of adult patients with hematologic malignancies who received chemotherapy in the intensive care unit (ICU). METHODS: This was a retrospective, single-center study comparing the outcomes of patients with hematologic malignancies who received chemotherapy in the ICU with a matched cohort of ICU patients who did not receive chemotherapy. Conditional logistic regression and shared-frailty Cox regression were used to assess short-term (ICU and hospital) mortality and death by 12 months after hospital discharge, respectively...
May 4, 2018: Cancer
https://www.readbyqxmd.com/read/29707136/bnip3-modulates-the-interface-between-b16-f10-melanoma-cells-and-immune-cells
#13
Erminia Romano, Nicole Rufo, Hannelie Korf, Chantal Mathieu, Abhishek D Garg, Patrizia Agostinis
The hypoxia responsive protein BNIP3, plays an important role in promoting cell death and/or autophagy, ultimately resulting in a cancer type-dependent, tumour-enhancer or tumour-suppressor activity. We previously reported that in melanoma cells, BNIP3 regulates cellular morphology, mitochondrial clearance, cellular viability and maintains protein expression of CD47, a pro-cancerous, immunosuppressive 'don't eat me' signal. Surface exposed CD47 is often up-regulated by cancer cells to avoid clearance by phagocytes and to suppress immunogenic cell death (ICD) elicited by anticancer therapies...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29681240/pembrolizumab-combined-with-stereotactic-body-radiotherapy-in-a-patient-with-human-immunodeficiency-virus-and-advanced-non-small-cell-lung-cancer-a-case-report
#14
Dongqi Li, Chuanchun He, Yaoxiong Xia, Yaxi Du, Jing Zhang
BACKGROUND: Pembrolizumab has significantly improved outcomes in patients with advanced non-small cell lung cancer. Combining programmed death-1 inhibitor with stereotactic body radiotherapy showed a slight toxicity and good benefits in recent clinical trials. However, patients infected with human immunodeficiency virus were excluded from most trials because it was assumed that their anti-tumor immunity was compromised compared with immunocompetent patients. CASE PRESENTATION: In June 2016, a 52-year-old Chinese man presented with human immunodeficiency virus and lung adenocarcinoma (T1bN3M1b)...
April 23, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29630020/disparities-in-adherence-to-national-comprehensive-cancer-network-treatment-guidelines-and-survival-for-stage-ib-iia-cervical-cancer-in-california
#15
Krista S Pfaendler, Jenny Chang, Argyrios Ziogas, Robert E Bristow, Kristine R Penner
OBJECTIVE: To evaluate the association of sociodemographic and hospital characteristics with adherence to National Comprehensive Cancer Network treatment guidelines for stage IB-IIA cervical cancer and to analyze the relationship between adherent care and survival. METHODS: This is a retrospective population-based cohort study of patients with stage IB-IIA invasive cervical cancer reported to the California Cancer Registry from January 1, 1995, through December 31, 2009...
May 2018: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29623487/atezolizumab-in-metastatic-urothelial-carcinoma-outside-clinical-trials-focus-on-efficacy-safety-and-response-to-subsequent-therapies
#16
Pedro C Barata, Dhrmesh Gopalakrishnan, Vadim S Koshkin, Prateek Mendiratta, Matt Karafa, Kimberly Allman, Allison Martin, Jennifer Beach, Pam Profusek, Allison Tyler, Laura Wood, Moshe Ornstein, Timothy Gilligan, Brian I Rini, Jorge A Garcia, Petros Grivas
BACKGROUND: Little is known about the outcomes, safety, and response to subsequent therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab outside clinical trials. OBJECTIVES: The objectives of the study include to report the clinical efficacy and safety of atezolizumab, and the response to future therapies in clinical practice outside clinical trials. PATIENT AND METHODS: This is a retrospective, single-center study including consecutive patients with confirmed mUC who received at least one dose of atezolizumab 1200 mg every 3 weeks between May 2016 and April 2017...
April 6, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29621999/histo-epidemiological-profile-of-breast-cancers-among-women-in-the-central-african-republic-about-174-cases
#17
Augustin Balekouzou, Ping Yin, Cavin Epi Bekolo, Christian Maucler Pamatika, Marceline Djeintote, Sylvain Wilfrid Nambei, Bertrand Ba-Mpoutou, Dieubeni Rawago Mandjiza, Chang Shu, Minghui Yin, Tingting Qing, Boniface Koffi
BACKGROUND: Breast cancer (BC) is the most common cancer in women worldwide and leading cause of cancer deaths indeveloping countries. There is very limited data on BC in the Central African Republic. The purpose of this study was to describe the epidemiological and histopathological characteristics of BC in Bangui. METHODS: This retrospective study reviewed cancer data registries and medical records from the Pathology Unit of the National Laboratory in Bangui and the General Surgery and Gyneacology service from 2003 to 2015...
April 5, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29588617/intensity-of-treatment-in-swiss-cancer-patients-at-the-end-of-life
#18
Caroline Bähler, Andri Signorell, Eva Blozik, Oliver Reich
Purpose: Current evidence on the care-delivering process and the intensity of treatment at the end-of-life of cancer patients is limited and remains unclear. Our objective was to examine the care-delivering processes in health care during the last months of life with real-life data of Swiss cancer patients. Patients and methods: The study population consisted of adult decedents in 2014 who were insured at Helsana Group. Data on the final cause of death were provided additionally by the Swiss Federal Statistical Office...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29587914/-surgical-treatment-of-refractory-chest-tumors-assisted-by-cardiopulmonary-bypass
#19
Rongying Zhu, Shanzhou Duan, Wentao Yang, Li Shi, Fuquan Zhang, Yongbing Chen
BACKGROUND: A retrospective review of the surgical treatment of refractory chest tumors involving the heart or large vessels with cardiopulmonary bypass (CPB). METHODS: To summarize 11 cases of chest tumor patients who had undergone cardiopulmonary bypass surgery from January 2008 to May 2017 in our hospital, and analyze the general condition, clinical characteristics, treatment methods, postoperative hospitalization time, complications and follow-up results of all patients...
April 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29555258/modified-xeliri-capecitabine-plus-irinotecan-versus-folfiri-leucovorin-fluorouracil-and-irinotecan-both-either-with-or-without-bevacizumab-as-second-line-therapy-for-metastatic-colorectal-cancer-axept-a-multicentre-open-label-randomised-non-inferiority-phase
#20
Rui-Hua Xu, Kei Muro, Satoshi Morita, Satoru Iwasa, Sae Won Han, Wei Wang, Masahito Kotaka, Masato Nakamura, Joong Bae Ahn, Yan-Hong Deng, Takeshi Kato, Sang-Hee Cho, Yi Ba, Hiroshi Matsuoka, Keun-Wook Lee, Tao Zhang, Yasuhide Yamada, Junichi Sakamoto, Young Suk Park, Tae Won Kim
BACKGROUND: Studies of a modified XELIRI (mXELIRI; capecitabine plus irinotecan) regimen suggest promising efficacy and tolerability profiles in the first-line and second-line settings. Therefore, we aimed to compare the efficacy and safety of the mXELIRI regimen with that of standard FOLFIRI (leucovorin, fluorouracil, and irinotecan), with or without bevacizumab in both regimens, as a second-line therapy for metastatic colorectal cancer. METHODS: We did a multicentre, open-label, randomised, non-inferiority, phase 3 trial...
May 2018: Lancet Oncology
keyword
keyword
67076
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"